EUVIMEDEUVIMED entdecken
Crossref

Hemgenix - A Gene Therapy for Hemophilia B

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1668a ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Hemophilia B, Hemophilia A. Die Arbeit wurde bisher 7-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Etranacogene dezaparvovec-drlb (Hemgenix – CSL Behring), an adeno-associated virus vector-based gene therapy, has been approved by the FDA for treatment of hemophilia B in adults who currently receive factor IX prophylaxis therapy or have had life-threatening or repeated, serious, spontaneous bleeding episodes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia BHemophilia AHumansGenetic Therapy

Stichwörter der Autor:innen

Hemgenixadverse effectsdosageefficacyetranacogene dezaparvovechemophiliasafety

Zitieren

APA

(2023). Hemgenix - A Gene Therapy for Hemophilia B. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668a

Vancouver

Hemgenix - A Gene Therapy for Hemophilia B. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668a

BibTeX
@article{euvimed2023,
  title = {Hemgenix - A Gene Therapy for Hemophilia B},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1668a}
}
Kostenlos starten →